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Objective: This study examined whether there is a positive correlation existed between cervical and oral High
Risk-Human Papilloma Viruses (HR-HPV) types 16, 18 infections in patients with clinically confirmed cervical lesions.
Methods: In this study 50 participants were included (40 were cases and 10 were controls). One hundred DNA
materials (50 were cervical and 50 were oral epithelial tissues) were analyzed using HR-HPV subtypes 16 and 18
specific PCR probes.
Results: Of the 40 cases, HR-HPV 16, 18 were identified in 16/40 (40%), of the cervical tissues of whom 8/16 (50%)
were positive for HPV 16; 6/16 (37.5%) were identified with HR-HPV 18, and 2/16 (12.5%) were detected with both
HR-HPV subtypes. All of the clinically healthy cases were found negative. Only one oral tissue sample (case) was 1/
40 (2.5%) was found positive for HPV subtype16.
Conclusion: The frequency of infection with HR-HPV subtypes 16 and 18 is high among Sudanese women with
cervical lesions and suggests a role of HR-HPV in the development of cervical cancer in Sudan. No correlation
between cervical and oral HPV infection was noted. Further study with screening of large number of patients with
cervical cancer is recommended for further clarification of these findings.
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Cervical cancer is the second most common cancer
found in women with approximately 530,000 new cases
each year resulting in an estimated 275,000 deaths,
worldwide. In developed countries, cervical cancer inci-
dences have declined, mostly due to cervical cytology
screening campaigns, which requires significant medical
resources and laboratory infrastructure. Cervical cancer
is on the rise in the developing world, with one-seventh
of the world’s cervical cancer cases in China, where no
nationwide screening program for the disease currently
exists [1]. In Sudan, cervical cancer is the second most
common cancer type among women [2] and there are
923 new cases representing 4.5/100,000 [3]. The
researchers have proposed that Human Papilloma
Viruses (HPV) testing of self-collected Pap specimens* Correspondence: elasbali2000@hotmail.com
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reproduction in any medium, provided the ormight serve as an alternative or complementary method
of a primary cervical cancer screening method [1]. As
long ago as 1995 the causative association between HPV
and Squamous Cell Carcinoma (SCC) was recognized
[4]. Epidemiological studies demonstrated that the major
risk factor for the development of pre-invasive and inva-
sive carcinoma of the cervix is HPV infection. In an
international study consisting of 1000 specimens from
patients with invasive cancer in 32 hospitals in 22 coun-
tries ,HPV-DNA was present in 99.7% of cervical can-
cers, HPV16 was the predominant type in all countries
except Indonesia where type 18 was more common[5].
HPVs are small, non-enveloped DNA viruses. HPV
infects and replicate within cutaneous and mucosal epi-
thelial tissues. The HPV family of viruses contains more
than 100 types. Approximately 40 HPV types affect the
genital area. They can be sub-divided into low risk for
cervical cancer and high risk [6]. The high risk are asso-
ciated with the development of cervical cancer includes
(types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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61, 70, 72, 81, and CP6108) can cause mild cervical dys-
plasia but are rarely associated with severe cervical dys-
plasia or cervical carcinoma [8,9].
HPV infection has also been postulated as a potential
risk factor for OSCC. Several studies have detected HPV
DNA in a considerable proportion of oral cancers, with
wide variations from 0% to 100% prevalence in oral tis-
sues, perhaps reflecting the inherent variations in the
different populations, [10-12].
In Sudan, invasive cervical cancer is a leading cause of
cancer death among women [13] . Most cervical cancers
are squamous cell carcinomas representing 90.9%, fol-
lowed by adenocarcinomas 4.8%, and other epithelial
tumors were 4.3%. Of the squamous carcinomas, 98.8%
were invasive and 1.2% intraepithelial (cervical intrae-
pithelial neoplasia). The majority of cases presenting
with a protruding cervical mass [14]. Although there are
many suggested risk factors for cervical cancer [15],
HPV remains the prime suspect.
Furthermore, a recent study has reported strong asso-
ciation between HPV types 16 and 18 and OSCC,
although, some prior studies have reported a lack [16]
or low association between HPV and OSCC among
Sudanese patients [17].
However, due to the lack of published data from Sudan
in this context, the aim of this study is to examine
whether there is a positive correlation existed between
cervical and oral HR-HPV types 16, 18 infections in
patients with clinically confirmed cervical lesions.
Materials and methods
Study design
In this descriptive study, 40 patients with clinically con-
firmed cervical lesions (cases) 10 clinically confirmed with
no cervical lesions (controls) were investigated for the pres-
ence of HR-HPV subtypes 16 and 18 PCR using molecular
techniques. All subjects were randomly selected from those
referred to gynecologic clinic at Al Nou hospital. All Parti-
cipants were with apparently healthy oral cavity.
Ethical consent
The study was approved by the ethics board of the
Faculty of Medical Laboratory Science, Sudan University
for Science and Technology. All cervical samples were
taken as a part of the specimens required for investiga-
tion. All study subjects were consented to participation
by completing the self-administered questionnaire.
Sample processing
The sample size represents a full coverage of patients
that were referred to the gynecologic clinic and agreed
to participate within 6 months period. One hundred
samples (50 cervical scrapes and 50 oral scrapes) werecollected as a part of the specimen required for screen-
ing for cervical cancer. Both cervical and oral cells were
obtained from the same person and processed similarly.
B scraped cells placed in sterile Caryo-tube containing
5 ml Tris–HCl buffer (PH 8.0) (preparation stock A 2.42
gm Tris in 100 cm3 of distill water, stock B 1.7 cm3
hydrochloric acid in 100 cm3 distill water, 25 cm3 of A
+ 13.4 of B made up to 100 cm3 with distill water). The
components were then centrifugated and the super-
natant was discarded, and the deposit was kept immedi-
ately in the refrigerator in −200 C.
DNA extraction
DNA was extracted according to the steps described in
DNA extraction kit purchased from Sacace biotechnologies-
Casera –Italy. The pellet obtained from previous steps was
treated with 300 μl of Reagent 2 (lysis buffer) in addition
100 μl of sample, vortexed, incubated at 65°C for 5 min and
centrifuged at (12000–16000 g) for 10 min and transfer the
supernatant into new tube (sterile 1.5 ml Eppendorf tube)
for DNA extraction . Vortexed vigorously sorbent and added
20 μl to each tube, Vortexed for 5–7 sec and incubated all
tubes for 3 min at room temperature, then this step was
repeated. Then all tubes were centrifugated for 30 sec at
5000 g and used amicropipette with aplugged aerosol barrier
tip, carefully removed and discarded supernatant from each
tube without disturbing the pellet. Tips was Changed be-
tween the tubes. 500 μl of Washing Solution was added to
each tube. Vortexed vigorously and centrifuged for 30 sec at
10000 g. Supernatant was removed and discarded from each
tube. This step was repeated and incubated all tubes with
open cap for 5–10 min at 65°C. The pellet was resuspended
in 100 μl of DNA-eluent. Incubate for 5 min at 65°C and
vortex periodically. The tubes were centrifuged for 1 min at
12000x g. The supernatant was containing DNA ready for
amplification stored at - 20°C until used.
Polymerase chain reaction (PCR) Amplification of HPV
Type specific primers (primer for HPV 16 and HPV18)
were used to detect HPV16 and 18 DNA in oral benign
and malignant lesion. Amplification was performed
according to HPV16/18 kit from Sacace-Biotechnologies
S.r.l. Caserta –Italy. The final reaction volume of 40 μl
containing 20 μl mix-1 (contained in PCR tubes), 10 μl of
mix-2 and 10 μl of extracted DNA (sample). Negative con-
trol, positive HPV16 DNA and positive control 18 DNA
tubes contained 10 μl of DNA buffer, 10 μl of HPV 16
DNA and10μl of HPV18 DNA respectively. Samples and
controls were amplified using Gene Amp PCR system
9700. The PCR program is described in Table 1.
Gel-electrophoresis
The PCR products were visualized in 2% Agarose gel
with 0.5 μg/ml Ethidium bromide. Ten micro liters of
Table 1 PCR steps
Cycles Time Tem PCR steps
Pause 95°C 0
1 5 min 95°C 1
42 15 sec 95°C 2
25 sec 65°C
25 sec 72°C
1 1 min 72°C 3
Storage 4°C 4
Table 2 Distribution of study population by age and
residence
Variable Category Cases Controls Total
No % No %
Age 18-25 8 20 3 30 11
26-35 21 52.5 5 50 26
36-45 6 15 1 10 7
46-70 5 12.5 1 10 6
Total 40 100 10 100 50
Resident North 13 32.5 4 40 17
West 12 30 2 20 14
East 3 7.5 0 0 3
Center 12 30 4 40 16
Total 40 100 10 100 50
Figure 1 Description of cases and controls by age 1.
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gel. Gel-electrophoresis was performed at 120 V and
36 mA for 60 minutes. Pictures were taken by Gel docu-
mentation system (Gel mega, digital camera and soft-
ware in a computer).
Interpretation of PCR results
According to manufacture HPV16/18 kit (Sacace-Bio-
technologies S.r.l. Caserta –Italy) manual, the PCR
product length for HPV16 should be 325 bp and
425 bp for HPV18.
Data analysis
Data management was done by using the Statistical
Package for Social Sciences (SPSS version 12; SPSS Inc,
Chicago, IL). SPSS was used for analysis and to perform
Fisher exact test for statistical significance (P value < 0.05
was considered significant). The 95% confidence level and
confidence intervals were used.
Results
A total of 40 cases (patients with clinically confirmed
cervical lesions) and 10 controls (patients without cer-
vical lesions) were included in this study. The age distri-
bution is relatively similar between cases and controls
with a range of 18 to 70 years and a mean age of
33 years. Most of cases were middle age 26–35 years
representing 21/40 (52.5%) followed by 18–25 group 8/
40 (20%), as indicated in Table 2, Figure 1. The distribu-
tion of the study population by resident is shown in
Table 1. Most of cases were from North followed by
West and Centre constituting 13/40 (32.5%), 12/40
(30%), 12/40 (30%), respectively.
Table 2 summarizes the results of High Risk (HR-HPV)
with other demographical factors. Of the 40 cases, HR-
HPV 16, 18 were identified in 16/40 (40%), of the cervical
tissues of whom 8/16 (50%) were positive for HPV 16;
6/16 (37.5%) were identified with HR-HPV 18, and 2/16
(12.5%) were detected with both HR-HPV subtypes, as
indicated in Table 2, Photomicrograph1 (Figure 2). All of
the clinically healthy cases were found negative. Only one
oral tissue sample (case) out of 40 (1/40 = 2.5%) was foundpositive for HPV subtype 16. According to age, a high rate
of infection with HR-HPV 16 was observed in among age
group 18–26 years representing 4/8 (50%) followed by age
range 26–35 representing 3/8 (37.5%). For infection with
HR-HPV 18, the highest frequency was detected among
age group 3/6 (50%) followed by age range 36–45 years
constituting 2/6 (33.3%). The 2/2 (100%) cases infected
with both HR-HPV 16&18 were found among age range
46–70 years, as shown in Table 3, Figure 3. According to
the residence high frequencies of infection with HR-HPV
16 were found among patients from Northern Sudan
representing 5/8 (62.5%) followed by Western Sudan 2/8
(25%), similarly, high frequencies of infection with HR-
HPV 18 were seen among patients from Northern Sudan
representing 5/6 (83.3%). Infections with both HR-HPV
16 & 18 were detected in two patients from Western
Sudan, as seen in Table 3, Figure 4.
Discussion
Worldwide, after breast cancer, cervical cancer is the
second most common cancer that affects women. In
99.7% of all cases, cervical cancer results from a history
of persistent infection by HR-HPV [5]. The high risk
Figure 2 Photomicrograph 1. Ethidium bromide stained agarose
gel 2% electrophoresis of HPV PCR products, carried out on DNA
samples extracted from fresh cells , Lane M:100 bp ladder, (Arrows
shows 300 and 400 band), Lane N negative control, Lane C1 positive
control for HPV16, Lane C2 positive control for HPV18,Lane 1-2-3-4-
5-6-7-8 extracted DNA samples. Figure 3 Description of the cases by HR-HPV infection.
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clude HPV-16 and HPV-18; together these account for
over 70% of SCCs [18]. HPV-18 is also thought to ac-
count for approximately 50% of all adenocarcinomas
[19]. Therefore, the present study mainly screened cer-
vical and oral cells for the presence of these two HR-
HPV subset.
HPV infection rates vary greatly between geographic
regions and population groups [20,21]. In the present
study, HR-HPV 16 and 18 were identified in 40% of the
cervical specimens. In a meta-analysis which was per-
formed on studies published between 1995 and 2009 that
used polymerase chain reaction or Hybrid Capture 2 for
HPV detection in women with normal cytological find-
ings. The analysis included 194 studies comprising
1,016,719 women with normal cytological findings. The
estimated global HPV prevalence was 11.7% (95% confi-
dence interval, 11.6%-11.7%). Sub-Saharan Africa (24.0%),
Eastern Europe (21.4%), and Latin America (16.1%)
showed the highest prevalences. Among the women with
type-specific HPV data (n = 215,568), the 5 most common
types worldwide were HPV-16 (3.2%), HPV-18 (1.4%),Table 3 Distribution of cases according to HPV DNA
detection in cervical cells
Variable category HR-HPV 16 HR-HPV 18 HR-HPV 16&18
+ve -ve +ve -ve +ve -ve
Age 18-25 4 4 0 8 0 8
26-35 3 18 3 18 0 21
36-45 1 5 2 4 0 6
46-70 0 5 1 4 2 5
Total 8 32 6 34 2 40
Resident North 5 8 5 8 0 13
West 2 10 1 11 2 10
East 0 3 0 3 0 3
Center 1 11 0 12 0 12
Total 8 32 6 34 2 38HPV-52 (0.9%), HPV-31 (0.8%), and HPV-58 (0.7%) [22].
Prevalence of cervical HPV infection in most African
countries is very high. HPV was detected in 100% of cer-
vical biopsies from 70 women with cervical cancer in
Papua New Guinea, with HPV types 16 and 18 being the
most prevalent at 57.1% and 25.7% (95% CI, 0.45-0.68 and
0.17-0.37) respectively [23]. High frequencies of HR-HPV
18 and 16 were reported from Egypt [24], Morocco [25],
59%, 56% respectively. The only one study from Sudan,
has reported 60.7% ß. globin positive samples for HPV in-
dicating DNA integrity [26]. The authors analyzed HPV
by general primer GP5+/6+ mediated PCR enzyme im-
munoassay (EIA) as described by Jacobs et al. [27] that its
used to detect a broad spectrum of human papilloma virus
(HPV) genotypes including the high-risk groups (HPV-
16,18,31,33,35,39,45,51,52,56,58,59,66, 68 and 73) and low
risk groups (HPV-6,11,40,42,43 and 44). Interestingly, the
most common high risk infection in their study group was
type 58, and in the low risk type 42.
In regard to age, most of positive cases were relatively
observed among younger women, and these findings
were consistent with global reports [28]. However, aFigure 4 Description of the HR-HPV subtypes 16 and 18 by
geographical distribution.
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bution presented with a first peak at younger ages
(< 25 years) and, in the Americas and Africa, a rebound
at older ages (≥ 45 years) [22].
According to the residence, most of cases were from
Northern Sudan. However, this might be due to the fact
that Northern Sudan consist the most civilized part of
the Sudan, this in addition to the fact the study was per-
formed in the Northern Sudan.
In this study, oral HPV infection was found to be very
low prevalent (2.5%) than cervical HPV infection (40%).
Most women with an oral HPV infection also had a cer-
vical infection, likely because the majority of women had
a cervical infection. The increased prevalence of oral
infections in women with simultaneous cervical infec-
tions would suggest that the behaviors that place a
woman at risk for oral HPV infection could substantially
overlap with cervical infection. Anogenital HPV infec-
tions in adults are predominantly sexually transmitted
[29], and indeed, sexual behaviors have been previously
associated with oral HPV infection [30]. Concomitant
type-specific infections at both anatomic sites could
be obtained during the same sexual encounter or se-
quential sexual encounters with an infected partner
or autoinoculation from one site to the other [31].
However, only one study from the Sudan in this con-
text has evaluated the possible role of high risk
Human Papilloma viruses (HPV) 16 and 18 in oral
squamous cell carcinomas (OSCC). HPVDNA was
detected in 15% of cases (six out of 40 cases), and
none of controls (n = 15), P < 0.0001 [32].Conclusion
HR-HPV types 16 and 18 are the most commonly
detected in Sudan and relatively similar to those
described in neighboring African countries, although the
relative contribution of HPV16 and HPV18 is sub-
stantially lower in cytologically normal women. The
oral and cervical infection for HPV infection are
likely independent of one another. Further more com-
prehensive studies are recommended for stronger
clarification of association between HPV infection and
cervical cancer in Sudan.
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